TABLE 1.

Characteristics of patients in study cohort^a

Clinical isolate	Date of isolation (day-mo-yr)	Ongoing treatment	No. of CD4 cells/μl	HIV-1 RNA load (no. of copies/ml)	Previous treatments	Time (mo) on PI therapy
001	11-11-1997	ZDV + ddI + IDV	562	10,240	ZDV, ddI	16
002	3-10-1997	d4T + ddI + IDV	508	11,620	ZDV, ddC, 3TC	11
003	5-12-1997	d4T + 3TC + RTV + SQV	28	36,170	ZDV, ddC, IDV	20
004	21-11-1997	d4T + 3TC + ddC + RTV + SQV	407	383,700	ZDV, ddC, RTV	29
005	25-07-1998	ddI + d4T + NVP + NFV	1,210	100,000	ZDV, ddI, 3TC, IDV, RTV	23
006	25-02-1997	d4T + ddI + RTV	20	77,500	ZDV, ddC	7
007	1-02-1997	ZDV + 3TC + IDV	175	490,000	ddI, DLV	0
008	1-01-1998	d4T + ddI + IDV	227	660	ZDV, 3TC, ddI, DLV	11
009	10-06-1998	d4T + SQV + NFV	410	140,000	ZDV, ddI, 3TC, IDV, RTV	25
010	17-10-1997	d4T + 3TC + IDV	224	184,800	ZDV, ddC, RTV, SQV	15

^aAbbreviations: ZDV, zidovudine; ddI, didanosine; d4T, stavudine; 3TC, lamivudine; ddC, zalcitabine; NVP, nevirapine; DLV, delavirdine.